In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Genelux Corp., with a price target of $20.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jason McCarthy has given his Buy rating due to a combination of factors that highlight the potential of Genelux Corp. in the oncolytic virus (OV) space. The company’s lead product, Olvi-Vec, is currently undergoing a pivotal Phase 3 trial for platinum-resistant ovarian cancer, with promising data from earlier Phase 2 studies that showed significant response rates and progression-free survival benefits. This ongoing trial, expected to yield top-line results in the second half of 2026, is a critical milestone for the company.
Additionally, Genelux’s partner-funded lung cancer programs are advancing, with key data updates anticipated by the end of 2025. These include interim results from a Phase 2 trial in non-small cell lung cancer and updates from a Phase 1b/2 study in small cell lung cancer. The broader OV sector is gaining momentum, as evidenced by recent regulatory advancements from other companies, which could provide favorable conditions for Genelux’s growth. Overall, the combination of promising clinical data, ongoing trials, and a dynamic OV market underpins McCarthy’s optimistic outlook on Genelux’s stock.
In another report released today, Lake Street also maintained a Buy rating on the stock with a $16.00 price target.